MX2017010982A - Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. - Google Patents
Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.Info
- Publication number
- MX2017010982A MX2017010982A MX2017010982A MX2017010982A MX2017010982A MX 2017010982 A MX2017010982 A MX 2017010982A MX 2017010982 A MX2017010982 A MX 2017010982A MX 2017010982 A MX2017010982 A MX 2017010982A MX 2017010982 A MX2017010982 A MX 2017010982A
- Authority
- MX
- Mexico
- Prior art keywords
- pridopidine
- subject
- cognitive function
- disease
- improve cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Esta invención proporciona un método para mejorar la función cognitiva en un sujeto, que comprende administrar periódicamente al sujeto una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para mejorar la función cognitiva en el sujeto. La invención también proporciona un método para tratar un sujeto que padece de enfermedad de Alzheimer, que comprende administrar periódicamente al sujeto una composición farmacéutica que comprende una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para tratar al sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120771P | 2015-02-25 | 2015-02-25 | |
| US201562186221P | 2015-06-29 | 2015-06-29 | |
| PCT/US2016/019357 WO2016138130A1 (en) | 2015-02-25 | 2016-02-24 | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010982A true MX2017010982A (es) | 2017-11-20 |
| MX378579B MX378579B (es) | 2025-03-11 |
Family
ID=56689699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010982A MX378579B (es) | 2015-02-25 | 2016-02-24 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| MX2021000071A MX2021000071A (es) | 2015-02-25 | 2017-08-25 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000071A MX2021000071A (es) | 2015-02-25 | 2017-08-25 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10603311B2 (es) |
| EP (4) | EP4282479A3 (es) |
| JP (2) | JP6887952B2 (es) |
| AU (2) | AU2016222796B2 (es) |
| CA (1) | CA2977264C (es) |
| DK (1) | DK3261721T3 (es) |
| ES (1) | ES2930628T3 (es) |
| HU (1) | HUE060353T2 (es) |
| IL (2) | IL254030B (es) |
| MX (2) | MX378579B (es) |
| PL (1) | PL3261721T3 (es) |
| TW (1) | TW201639570A (es) |
| WO (1) | WO2016138130A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) * | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) * | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| US20210093622A1 (en) * | 2016-09-15 | 2021-04-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of anxiety and depression |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) * | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| CA3050700C (en) * | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| HRP20251431T1 (hr) * | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CN113597310A (zh) * | 2019-03-15 | 2021-11-02 | 普瑞尼亚神经治疗有限公司 | 使用普利多匹定治疗线粒体相关疾病和病症，包含其症状 |
| CN116059192B (zh) | 2019-11-13 | 2024-10-29 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69231854T2 (de) | 1991-04-17 | 2001-10-04 | Pharmacia & Upjohn Co., Kalamazoo | Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| SE9702716D0 (sv) * | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP4847320B2 (ja) * | 2004-02-20 | 2011-12-28 | 大日本住友製薬株式会社 | 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法 |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| EP2508177A1 (en) * | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| DK2421519T3 (en) | 2009-04-23 | 2017-02-06 | Univ Zuerich | NMDA RECEPTOR BLOCKERS FOR THE TREATMENT OF SEAL CELL ANAEMS |
| EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US8849866B2 (en) | 2010-02-22 | 2014-09-30 | Infosys Limited | Method and computer program product for creating ordered data structure |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| PL2578212T3 (pl) | 2010-05-24 | 2017-01-31 | Farmalider Sa | Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| JP6396438B2 (ja) * | 2013-06-04 | 2018-09-26 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
-
2016
- 2016-02-24 EP EP23198399.0A patent/EP4282479A3/en not_active Withdrawn
- 2016-02-24 EP EP19191835.8A patent/EP3590512A1/en not_active Withdrawn
- 2016-02-24 JP JP2017545405A patent/JP6887952B2/ja active Active
- 2016-02-24 PL PL16756274.3T patent/PL3261721T3/pl unknown
- 2016-02-24 AU AU2016222796A patent/AU2016222796B2/en active Active
- 2016-02-24 EP EP21153340.1A patent/EP3854785A1/en not_active Ceased
- 2016-02-24 WO PCT/US2016/019357 patent/WO2016138130A1/en not_active Ceased
- 2016-02-24 CA CA2977264A patent/CA2977264C/en active Active
- 2016-02-24 MX MX2017010982A patent/MX378579B/es unknown
- 2016-02-24 EP EP16756274.3A patent/EP3261721B1/en active Active
- 2016-02-24 ES ES16756274T patent/ES2930628T3/es active Active
- 2016-02-24 DK DK16756274.3T patent/DK3261721T3/da active
- 2016-02-24 HU HUE16756274A patent/HUE060353T2/hu unknown
- 2016-02-24 US US15/052,368 patent/US10603311B2/en active Active
- 2016-02-25 TW TW105105721A patent/TW201639570A/zh unknown
-
2017
- 2017-08-16 IL IL254030A patent/IL254030B/en unknown
- 2017-08-25 MX MX2021000071A patent/MX2021000071A/es unknown
-
2021
- 2021-01-07 JP JP2021001418A patent/JP7210620B2/ja active Active
- 2021-03-12 AU AU2021201583A patent/AU2021201583B2/en active Active
- 2021-09-30 IL IL286888A patent/IL286888A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016222796B2 (en) | 2021-07-15 |
| WO2016138130A1 (en) | 2016-09-01 |
| JP2018506569A (ja) | 2018-03-08 |
| AU2021201583A1 (en) | 2021-04-01 |
| IL254030A0 (en) | 2017-10-31 |
| EP3261721A1 (en) | 2018-01-03 |
| MX378579B (es) | 2025-03-11 |
| JP6887952B2 (ja) | 2021-06-16 |
| PL3261721T3 (pl) | 2022-12-27 |
| ES2930628T3 (es) | 2022-12-20 |
| TW201639570A (zh) | 2016-11-16 |
| US10603311B2 (en) | 2020-03-31 |
| MX2021000071A (es) | 2021-03-25 |
| AU2021201583B2 (en) | 2022-04-07 |
| HUE060353T2 (hu) | 2023-02-28 |
| EP4282479A2 (en) | 2023-11-29 |
| JP7210620B2 (ja) | 2023-01-23 |
| EP3590512A1 (en) | 2020-01-08 |
| JP2021073206A (ja) | 2021-05-13 |
| US20160243098A1 (en) | 2016-08-25 |
| CA2977264A1 (en) | 2016-09-01 |
| CA2977264C (en) | 2021-12-07 |
| IL286888A (en) | 2021-10-31 |
| EP3854785A1 (en) | 2021-07-28 |
| AU2016222796A1 (en) | 2017-10-05 |
| DK3261721T3 (da) | 2022-11-28 |
| EP4282479A3 (en) | 2024-02-21 |
| EP3261721A4 (en) | 2018-08-08 |
| IL254030B (en) | 2022-01-01 |
| EP3261721B1 (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CL2019000268A1 (es) | Composición de cannabis. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| CO6630085A2 (es) | Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX2016008968A (es) | Compuestos organicos. | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) |